TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
CLYM

Climb Bio Inc

Healthcare · Biotechnology

14.10$ -0.1% vs. previous close Closing price · As of: Sep 18, 2026

Ownership

Ownership Structure

Who owns Climb Bio Inc (CLYM)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 72.4% of the shares are freely tradable; institutional investors hold 66.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 66.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.4%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 72.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 17.9%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 57Mio.

Largest Shareholders

Institutions

Institutions CLYM
Name Stake (%) Shares Change (%) Date
RA Capital Management, LLC 19.68 11,300,939 +0.1 03/31/2026
Adage Capital Partners Gp LLC 4.36 2,506,000 +0.0 06/30/2026
Frontier Capital Management CO Inc 3.38 1,939,019 +0.0 06/30/2026
T. Rowe Price Associates, Inc. 3.34 1,916,968 -0.3 03/31/2026
BRAIDWELL LP 2.66 1,529,675 +0.0 03/31/2026
Citadel Advisors Llc 2.26 1,297,972 +275.5 06/30/2026
Redmile Group, LLC 2.14 1,226,330 +0.0 06/30/2026

Funds

Funds CLYM
Name Stake (%) Shares Change (%) Date
T. Rowe Price Health Sciences 3.49 2,005,273 +22.6 07/31/2026
Fidelity Small Cap Growth 3.13 1,796,386 +80.2 06/30/2026
Vanguard MStar Total Stk Mkt Idx Invest 2.38 1,366,686 +0.0 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider holdings

Insider holdings CLYM
Person Role Shares Value As of Type
Thomas Stephen Basil Director 467,969 6,598,363 $ Sep 15, 2026 direct

Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.

Insiders

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
Sep 15, 2026 Thomas Stephen Basil Director Sell 100,000 13.67 1,366,820

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?